<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2006">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012346</url>
  </required_header>
  <id_info>
    <org_study_id>NV16-31868A</org_study_id>
    <nct_id>NCT04012346</nct_id>
  </id_info>
  <brief_title>Modulation of Cognition and Brain Connectivity by Noninvasive Brain Stimulation in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease</brief_title>
  <acronym>LUSTR</acronym>
  <official_title>Modulation of Cognition and Brain Connectivity by Noninvasive Brain Stimulation in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masaryk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Anne's University Hospital Brno, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Masaryk University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease (AD) has a detrimental impact on cognitive functions. Based on pilot&#xD;
      studies results in patients with neurodegenerative brain diseases the investigators aim for&#xD;
      promoting the brain plasticity and improving cognition by noninvasive brain stimulation&#xD;
      (NIBS) in healthy young, healthy aged and subjects with mild cognitive impairment due to AD.&#xD;
      Mild cognitive impairment (MCI) is an intermediate stage between the expected cognitive&#xD;
      decline of normal aging and the more-serious decline of dementia. Different new brain&#xD;
      targets, cognitive tasks and stimulation protocols will be tested and optimized for specific&#xD;
      subject groups. Design of a functional MRI (fMRI) - repetitive transcranial magnetic&#xD;
      stimulation (rTMS) - fMRI study will enable us to explore and identify effect of age,&#xD;
      presence of the disease and genetic risk factor (APOE4) on repetitive transcranial magnetic&#xD;
      stimulation (rTMS)-induced changes in cognition and related brain connectivity/activations.&#xD;
      The study results will improve our understanding of healthy and pathological brain aging and&#xD;
      will provide novel information about the usefulness of NIBS in specific subject groups. These&#xD;
      results will have an important impact on future non-pharmacological treatment strategies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intensified intermittent theta-burst stimulation (iTBS) protocol will be applied in the MCI&#xD;
      study group. A two-parallel-group, randomized, placebo controlled design will be used. Ten&#xD;
      MCI subjects will be stimulated in a week-long therapeutical sessions. Other ten MCI subjects&#xD;
      will be stimulated with the same protocol using sham stimulation. The investigators will&#xD;
      study the change in subjects immediately after and again at a two-weeks follow-up visit after&#xD;
      the end of the last stimulation session.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual-attention task accuracy and reaction times</measure>
    <time_frame>On the beginning of the study, after completion of week stimulation a two weeks after completion of stimulation sessions.</time_frame>
    <description>Stroop task will be presented in fMRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting state measurement</measure>
    <time_frame>On the beginning of the study, after completion of week stimulation a two weeks after completion of stimulation sessions.</time_frame>
    <description>The effect of stimulation on the resting state networks will be studied using fMRI measurement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Active Comparator: MCI patients with real iTBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive real iTBS in a week-long sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Comparator: MCI patients with sham iTBS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive sham iTBS in a week-long sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial magnetic stimulation</intervention_name>
    <description>Transcranial magnetic stimulation device will be used. Short protocol iTBS will be applied.</description>
    <arm_group_label>Active Comparator: MCI patients with real iTBS</arm_group_label>
    <arm_group_label>Sham Comparator: MCI patients with sham iTBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  amnestic single or multi-domain mild cognitive impairment patients in accordance with&#xD;
             diagnostic criteria (Albert et al., 2011)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        psychiatric disorders, including major depression, major vascular lesions, and other brain&#xD;
        pathologies detected by MRI that might present with cognitive decline&#xD;
&#xD;
          -  a cardio pacemaker or any MRI-incompatible metal in the body&#xD;
&#xD;
          -  epilepsy&#xD;
&#xD;
          -  any diagnosed psychiatric disorder&#xD;
&#xD;
          -  alcohol/drug abuse&#xD;
&#xD;
          -  lack of cooperation&#xD;
&#xD;
          -  presence of dementia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lubomira Anderkova, PhD</last_name>
    <phone>+420 549 497 766</phone>
    <email>lubomira.anderkova@ceitec.muni.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ceitec Masaryk University</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lubomira Anderkova, PhD</last_name>
      <phone>+420 549 497 766</phone>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 5, 2019</last_update_submitted>
  <last_update_submitted_qc>July 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

